Literature DB >> 9815776

Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states.

N Suehara1, K Mizumoto, T Muta, Y Tominaga, H Shimura, S Kitajima, N Hamasaki, M Tsuneyoshi, M Tanaka.   

Abstract

Telomerase activity was measured in surgically resected tissues of 20 human pancreatic ductal carcinomas, 12 adenomas, 5 pancreatitis tissues, 14 normal pancreatic ducts, and 13 normal pancreatic tissues (primarily made up of acinar cells) using a PCR-based telomerase assay. Relative telomerase activity was expressed as the equivalent telomerase intensity of the number of cells of a human pancreatic cancer cell line, MIA PaCa-2, per microgram of protein in the tissue samples. The median value (25th percentile, 75th percentile) of relative telomerase activity in pancreatic carcinomas was 13.2 (3.58, 244), which was significantly higher relative to normal tissues, normal ducts, pancreatitis tissues, and adenomas (P < 0.0001). When the cutoff value of relative telomerase activity was set at 1.00 and 3.00, the positivity rates of telomerase activity in pancreatic ductal carcinomas were 100 and 80%, respectively. Some of the adenoma samples displayed a weak telomerase ladder. However, when semiquantitatively analyzed, the relative telomerase activity of all adenoma tissues was less than 1.00 equivalent cells per microgram protein of the tissues, which was equivalent to the values encountered in normal ducts. Thus, our results indicate that reactivation of telomerase may occur at a late stage of pancreatic ductal carcinogenesis. Therefore, telomerase may be a specific marker for distinguishing pancreatic cancer from pancreatitis and adenomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815776

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Inherited predisposition to pancreatic cancer.

Authors:  E Efthimiou; T Crnogorac-Jurcevic; N R Lemoine; T A Brentnall
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 2.  Immunotherapy in pancreatic cancer treatment: a new frontier.

Authors:  Komal Thind; Leslie J Padrnos; Ramesh K Ramanathan; Mitesh J Borad
Journal:  Therap Adv Gastroenterol       Date:  2016-10-17       Impact factor: 4.409

3.  Telomerase activity in periampullary tumors correlates with aggressive malignancy.

Authors:  J H Balcom; T Keck; A L Warshaw; B Antoniu; F Graeme-Cook; C Fernández-del Castillo
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

4.  Pancreatic intraepithelial neoplasia-3 with localized acute pancreatitis in the main pancreatic duct.

Authors:  Takaho Okada; Fuyuhiko Motoi; Atsushi Kanno; Atsushi Masamune; Kazuyuki Ishida; Fumiyoshi Fujishima; Toshiki Rikiyama; Yu Katayose; Shinichi Egawa; Tooru Shimosegawa; Michiaki Unno
Journal:  Clin J Gastroenterol       Date:  2013-02-23

Review 5.  Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer.

Authors:  Lukas Perkhofer; Alica K Beutel; Thomas J Ettrich
Journal:  Visc Med       Date:  2019-02-07

6.  Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer.

Authors:  Guo-Xiong Zhou; Jie-Fei Huang; Zhao-Shen Li; Guo-Ming Xu; Feng Liu; Hong Zhang
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

7.  The molecular biology of pancreatic cancer.

Authors:  Michael A Abramson; Amarsanaa Jazag; Jill A van der Zee; Edward E Whang
Journal:  Gastrointest Cancer Res       Date:  2007

8.  Quantitative assessment of the diagnostic role of human telomerase activity from pancreatic juice in pancreatic cancer.

Authors:  Siliang Wang; Xiaodong Chen; Meiyue Tang
Journal:  Tumour Biol       Date:  2014-05-15

Review 9.  Pancreatic Cancer: Clinical Significance of Biomarkers.

Authors:  Kenoki Ohuchida; Takao Ohtsuka; Kazuhiro Mizumoto; Makoto Hashizume; Masao Tanaka
Journal:  Gastrointest Tumors       Date:  2013-09-12

Review 10.  Targeted therapies for pancreatic cancer.

Authors:  S A Danovi; H H Wong; N R Lemoine
Journal:  Br Med Bull       Date:  2008-08-27       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.